首页> 外文期刊>American Journal of Dermatopathology >Immunolabeling pattern of podoplanin (d2-40) may distinguish basal cell carcinomas from trichoepitheliomas: a clinicopathologic and immunohistochemical study of 49 cases.
【24h】

Immunolabeling pattern of podoplanin (d2-40) may distinguish basal cell carcinomas from trichoepitheliomas: a clinicopathologic and immunohistochemical study of 49 cases.

机译:Podoplanin(d2-40)的免疫标记模式可能将基底细胞癌与毛细血管上皮瘤区分开:49例临床病理和免疫组织化学研究。

获取原文
获取原文并翻译 | 示例
           

摘要

When the morphologic distinction between basal cell carcinomas (BCCs) and tichoepitheliomas is unclear, it poses a rare diagnostic challenge as the commonly defined histologic criterion is insufficient for differentiating these two neoplasms from each other. Their distinction is clinically important because the risk of progressive disease in BCC can be problematic, and trichoepitheliomas misinterpreted as BCC burdens the patient with an inaccurate diagnosis and consequential inappropriate surgery. Podoplanin (D2-40) is a well-known lymphatic endothelial surface marker that has been postulated to be upregulated in the outer root sheath of hair follicles and cutaneous neoplasms, such as adnexal tumors, squamous cell carcinomas, etc. We studied the expression of D2-40 by immunohistochemistry to determine if this marker could reliably differentiate these neoplasms from each other. A total of 49 cutaneous tumors, including 22 cases of trichoepitheliomas and 27 cases of BCC were examined. Of the 27 cases of BCC, 18 cases were located in the head and neck area, 5 on upper extremities, and 4 on the back. Of the 22 cases of trichoepitheliomas, all were from the head and neck area. D2-40 expression was present in 21/22 cases of trichoepitheliomas; 11 cases were diffusely positive (50%), 10 cases were focally positive (45.5%), and 1 case was negative (4.5%). D2-40 expression was present in 6/27 cases of BCC; 2 cases were diffusely positive (7.4%), 4 cases were focally positive (14.8%), and 21 cases were negative (77.8%). In summary, D2-40 expression was only weakly and focally positive in BCC (22.2% of cases) and diffusely and weakly positive in trichoepitheliomas (95.5% of cases). The sensitivity and specificity of D2-40 immunoreactivity to separate trichoepitheliomas from BCCs was 95.5% and 77.8%, respectively. This data suggests that D2-40 expression could be a useful potential marker to distinguish BCCs from trichoepitheliomas, especially when there is a high index of histologic suspicion for either of these two tumors. Our results also suggest that BCC can show differentiation toward the outer root sheath of hair follicles.
机译:当基底细胞癌(BCC)和上皮性上皮瘤之间的形态学区别不清楚时,它提出了罕见的诊断挑战,因为通常定义的组织学标准不足以区分这两种肿瘤。它们的区别在临床上很重要,因为在BCC中进行性疾病的风险可能会成问题,并且误诊为BCC的毛细上皮瘤会使患者负担不正确的诊断和随之而来的不适当的手术。 Podoplanin(D2-40)是一种众所周知的淋巴管内皮表面标志物,被假定在毛囊和皮肤肿瘤(如附件瘤,鳞状细胞癌等)的外根鞘中上调。我们研究了通过免疫组织化学D2-40来确定该标记物是否可以可靠地将这些肿瘤相互区分。共检查了49例皮肤肿瘤,其中包括22例毛发上皮瘤和27例BCC。在27例BCC病例中,有18例位于头颈部区域,5例位于上肢,4例位于背部。在22例毛发上皮瘤中,全部来自头颈部区域。在21/22例毛状上皮瘤中存在D2-40表达;弥漫阳性11例(50%),局灶性阳性10例(45.5%),阴性1例(4.5%)。 6/27例BCC中存在D2-40表达;弥漫性阳性2例(7.4%),局灶性阳性4例(14.8%),阴性21例(77.8%)。总之,D2-40表达在BCC中仅弱和灶性阳性(占22.2%的病例),而在三叉神经上皮瘤中则呈弥散性和弱阳性(占95.5%的病例)。 D2-40免疫反应活性对从BCC中分离出毛状上皮瘤的敏感性和特异性分别为95.5%和77.8%。该数据表明,D2-40表达可能是区分BCC与毛发上皮瘤的有用的潜在标志物,尤其是当这两个肿瘤中任何一个的组织学怀疑指数较高时。我们的结果还表明,BCC可以显示出向毛囊外根鞘的分化。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号